PDGFRA, KIT, and KDR Gene Amplification in Glioblastoma: Heterogeneity and Clinical Significance

Brain Glioblastoma PDGFRA, KIT and KDR Gene Amplification: Heterogeneity and Its Clinical Significance Academic Background Glioblastoma (GBM) is the most common malignant tumor of the central nervous system, with its heterogeneity posing significant challenges in treatment. GBM exhibits cellular genetic and phenotypic diversity not only between dif...

Single-cell atlas reveals the immunosuppressive microenvironment and Treg cells landscapes in recurrent glioblastoma

Single-Cell Atlas Reveals Immunosuppressive Microenvironment and Treg Cell Distribution in Recurrent Glioblastoma Glioblastoma is the most aggressive brain tumor, with a very high recurrence rate and poor prognosis. Although many studies have explored the tumor microenvironment of this disease, the understanding of the immune microenvironment in re...

Leptomeningeal Metastases in IDH-Wildtype Glioblastomas Revisited: Comprehensive Analysis of Incidence, Risk Factors, and Prognosis Based on Post-Contrast FLAIR

Comprehensive Analysis of Leptomeningeal Metastasis in IDH Wild-Type Glioblastoma In this article published in the journal “Neuro-Oncology,” the research team starting in 2024 delves into the incidence, risk factors, and prognosis of leptomeningeal metastases (LM) in patients with isocitrate dehydrogenase (IDH) wild-type glioblastoma. This study wa...

Extent of Resection Thresholds in Molecular Subgroups of Newly Diagnosed Isocitrate Dehydrogenase–Wildtype Glioblastoma

Extent of Resection Thresholds in Molecular Subgroups of Newly Diagnosed Isocitrate Dehydrogenase–Wildtype Glioblastoma

Study on the Extent of Resection Threshold in Different Molecular Subtypes of Newly Diagnosed IDH-wildtype Glioblastoma Introduction Glioblastoma (GBM) is the most common malignant brain tumor in adults. Although surgical resection, radiotherapy, and chemotherapy are the current standard treatment regimens, the prognosis of GBM remains poor, with a...

Immunotherapy drives mesenchymal tumour cell state shift and TME immune response in glioblastoma patients

Immunotherapy Drives Mesenchymal Transition and Tumor Microenvironment Immune Response in Glioblastoma Introduction Glioblastoma is a highly malignant brain tumor with no curative treatment currently available. Although immunotherapy has shown efficacy in other cancer types, the response in glioblastoma patients is limited. Investigating the effect...

TREM2 mediates MHC II-associated CD4+ T-cell response against gliomas

The human genome-encoded triggering receptor expressed on myeloid cells 2 (TREM2) was initially thought to play a role primarily in the central nervous system, participating in the functional regulation of microglia. In recent years, researchers have found that TREM2 is also expressed in peripheral tumors and may promote tumor progression. However,...

Circulating Extracellular Vesicles as Biomarker for Diagnosis, Prognosis and Monitoring in Glioblastoma Patients

This academic paper reports a study on exosomes in patients with glioblastoma. The study explored the potential application of exosomes as biomarkers in the diagnosis, prognosis, and treatment response monitoring of glioblastoma. Academic Background: Glioblastoma is an invasive brain tumor, and despite comprehensive treatments such as surgery, chem...

Radical surgical resection with molecular margins is associated with improved survival in IDH wildtype GBM

In this research paper from the journal Neuro-Oncology, the researchers investigated the relationship between the residual tumor cells at the resection margin after surgical removal and the progression-free survival (PFS) and overall survival (OS) in patients with wildtype isocitrate dehydrogenase (IDH wildtype) glioblastoma (GBM). The authors are ...